Fresenius FRE.DE
Fresenius is a German healthcare group operating in two main areas: hospital and clinic management (Fresenius Helios) and the production of dialysis products and services (Fresenius Medical Care). Fresenius presents an attractive valuation (P/E 16.98, forward P/E 11.90, PEG 0.82) and earnings growth of 17.20%, supported by its improved annual guidance. However, its high leverage (Net Debt/EBITDA 3.34) and modest ROE (8.29%) limit the quality of its financial profile.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Fresenius is a German healthcare group operating in two main areas: hospital and clinic management (Fresenius Helios) and the production of dialysis products and services (Fresenius Medical Care). Fresenius presents an attractive valuation (P/E 16.98, forward P/E 11.90, PEG 0.82) and earnings growth of 17.20%, supported by its improved annual guidance. However, its high leverage (Net Debt/EBITDA 3.34) and modest ROE (8.29%) limit the quality of its financial profile.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.7 |
| Quality / Moat | 4.5 |
| Valuation | 7.1 |
| Growth | 6.6 |
| Dividend | 6.6 |
| Momentum | 5.0 |
| Risk & Context | 6.8 |
OVERALL SCORE: 5.9/10
Context and risks
Moderate regulatory risk in Germany for the healthcare sector, with potential pressure on prices and reimbursements in the hospital business (Helios).
News considered in the analysis
- Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock? (Zacks) — Artículo de opinión genérico de Zacks sin información nueva sobre la empresa.
- All You Need to Know About Fresenius SE & Co. (FSNUY) Rating Upgrade to Buy (Zacks) — Upgrade de analista a 'Comprar' por parte de Zacks, una señal moderadamente positiva que puede atraer flujo de compra.
- Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now? (Zacks) — Artículo de opinión especulativo sobre la valoración, sin hechos concretos nuevos.
- Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ... (GuruFocus.com) — Noticia material: la empresa ha elevado su guía de BPA para el año completo, lo que indica una mejora en las perspectivas de beneficios.
- Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings? (Zacks) — Noticia sobre un competidor (DaVita) sin impacto directo en los fundamentales de Fresenius.
Verdict: Hold, with a positive bias. The improved guidance and cheap valuation offer a good entry point, but the debt and average business quality warrant caution.
Main risk: The high leverage (Net Debt/EBITDA of 3.34) in an environment of rising rates by the ECB, which could pressure financial health and limit flexibility to invest in growth.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →